NLRP3 Inflammasome and Pyroptosis: Pathway, Function and Assays

The inflammasome is one of the few innate pathways that destroys the cell it activates. A macrophage that assembles NLRP3 has committed to a decision it cannot reverse: a priming signal through TLR4 and NF-κB stocks the cytosol with inactive precursors, then an entirely separate second signal nucleates an ASC speck, activates caspase-1 and punches gasdermin-D pores through its own membrane. The output — IL-1β and IL-18 leaving through those pores — drives fever, neutrophil recruitment and, when the brakes fail, hereditary autoinflammatory disease.

Signal 1: priming through TLR4 and NF-κB

A resting macrophage carries almost no NLRP3 and no pro-IL-1β. Priming supplies both. TLR4, working with MD-2 and CD14, engages LPS and signals through MyD88, IRAK4 and TRAF6 to TAK1 and the IKK complex, freeing NF-κB p65/p50 to enter the nucleus and induce Nlrp3 and Il1b. Without this step the sensor sits at levels too low to nucleate anything, which is why an ex vivo stimulation that omits an LPS pre-incubation reliably reads flat.

Priming is not purely transcriptional, and the consequences are asymmetric. Within ten minutes, long before new protein appears, the deubiquitinase BRCC3 strips inhibitory K63 chains from the NLRP3 LRR domain, licensing the existing pool. Meanwhile pro-IL-1β is absent until NF-κB makes it, whereas pro-IL-18 is constitutive in macrophages and epithelium. The same trigger therefore yields IL-18 immediately but IL-1β only in proportion to how well the cell was primed.

Signal 2: what actually activates NLRP3

NLRP3 responds to nigericin, extracellular ATP, monosodium urate, silica, alum, cholesterol crystals and pore-forming toxins — agonists with no shared chemistry. The resolution is that NLRP3 is a receptor for none of them. It reads a downstream perturbation, and the most reproducible one is a fall in cytosolic K⁺. P2X7 makes this explicit: a non-selective cation channel gated only by millimolar extracellular ATP, concentrations reached when neighbouring cells lyse, so it converts local cell death into a K⁺-efflux signal.

Particulates converge on the same point by a different route, destabilising the lysosome and releasing cathepsin B into the cytosol. Loss of K⁺ then lets NEK7 bridge adjacent NLRP3 subunits through their LRR domains. NEK7 is both the licensing step and a scheduling constraint: because it is otherwise committed to mitotic spindle assembly, a dividing cell cannot mount an NLRP3 response. Raising extracellular KCl to 40–50 mM is the cleanest specificity control — it blocks NLRP3 while leaving AIM2 and NLRC4 largely intact.

One adaptor, three sensors: ASC, AIM2 and NLRC4

ASC (PYCARD) is a two-domain adaptor and nothing else: a PYD that binds sensor PYDs and a CARD that binds caspase-1. Its behaviour is what makes the pathway unusual. Nucleated ASC polymerises in prion-like fashion into filaments that condense into a single perinuclear speck about a micron across, one per cell. Because nucleation is rate-limiting and elongation is not, a cell either forms a speck or it does not — activation is digital, and population-averaged cytokine data hides that completely.

AIM2 feeds the same adaptor from a different input: its HIN-200 domain binds the sugar-phosphate backbone of cytosolic double-stranded DNA without sequence specificity. NLRC4 carries its own CARD and does not strictly require ASC, but it never binds ligand itself — NAIP proteins detect flagellin and type III secretion rod and needle proteins, then recruit NLRC4 into a wheel-shaped oligomer. So an ASC-deficient phenotype identifies the branch but not the sensor; stimulus-matched controls are the only way to separate them.

Caspase-1 and the gasdermin-D pore

The ASC CARD filament recruits pro-caspase-1 through CARD–CARD contacts and activates it by proximity: clustering forces dimerisation, dimerisation builds the active site, autoprocessing into p20 and p10 follows. Order matters, because filament-bound caspase-1 cleaves substrate before it self-processes and the released tetramer is short-lived. A caspase-1 ELISA therefore reports enzyme abundance rather than activity, and is best paired with an activity probe or with detection of a cleaved substrate.

The substrate list is short: pro-IL-1β to its 17 kDa form, pro-IL-18 to its 18 kDa form, and gasdermin-D at a single aspartate in the interdomain linker. The freed N-terminal fragment binds acidic inner-leaflet lipids, not the neutral outer leaflet, which is why the pore forms in the cell that made it and not in its neighbours. The resulting β-barrel is 10–20 nm across and selects by size and charge, so mature cytokines pass and the bulkier pro-forms do not.

IL-1β, IL-18 and where the pathway is targeted

Sustained pore formation causes osmotic swelling and NINJ1-dependent membrane rupture, but ESCRT-III repair can keep a cell alive and secreting — the hyperactivated state, and the reason supernatant IL-1β does not always track with LDH release. IL-1β then acts on IL-1R1 and signals through MyD88 back to NF-κB, the same node that primed the pathway. That feed-forward loop turns a local event into fever and acute-phase response, restrained by IL-1Ra and the decoy receptor IL-1R2.

IL-18 instead drives IFN-γ from NK and Th1 cells and is buffered by IL-18BP in large molar excess, so total and free levels diverge widely. Clinically the axis is well validated: gain-of-function NLRP3 mutations cause the cryopyrin-associated periodic syndromes, gout is urate acting on the same sensor, and canakinumab lowered cardiovascular events in CANTOS. NLRC4 gain-of-function instead produces macrophage activation syndrome with extreme IL-18 — which is precisely why the two cytokines should be measured separately.

Key targets and matching reagents

Studying the inflammasome in vivo

This is a two-signal pathway with a proteolytic core and a soluble output, so useful experiments generally attack one of three layers.

1. Controlling and measuring the priming arm

Almost every model begins with an LPS prime, so priming is a variable to be measured, not assumed. Quantify TLR4, NF-κB p65 and induced NLRP3 in the same lysate to confirm the pathway was loaded before the trigger. Endotoxin in any co-administered antibody is a real confound: trace LPS is itself a priming signal, so low-endotoxin material from the In Vivo range is the only sensible choice.

2. Dissecting the activation step

Match the stimulus to the sensor and read the core components together. ATP or nigericin with P2X7 quantitation addresses the K⁺-efflux route; transfected dsDNA implicates AIM2; flagellin or a Salmonella challenge implicates NLRC4. Pair these with ASC and caspase-1 measurement, and use extracellular KCl as the control that separates canonical NLRP3 activation from sensors that do not depend on ionic flux.

3. Neutralising the output

The output layer is where blockade is most tractable. Anti-mouse IL-1β (low endotoxin) neutralises the dominant effector and phenocopies clinical IL-1 blockade, while serum IL-18 tracks the arm that IL-1 blockade does not touch. Add gasdermin-D and LDH to distinguish release through intact pores from frank pyroptotic lysis.

Featured products for this pathway

Frequently asked questions

For research use only. Not for use in diagnostic or therapeutic procedures.